NL-OMON27624尚未招募不适用
International, multi-center, open-label, randomized controlled trial in patients undergoing TAVR to evaluate the Effect of Bivalirudin on Aortic Valve Intervention.
The Medicines Company8 Sylvan WayParsippany, NJ070540 个研究点目标入组 620 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 620
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. ≥ 18 years of age;
- •2. High risk (Euroscore ≥18, or considered inoperable) for surgical aortic valve replacement;
排除标准
- •1. Contraindication to bivalirudin or UFH;
- •2. Refusal to receive blood transfusion;
研究者
相似试验
进行中（未招募）
1 期
A Study of Avapritinib vs Regorafenib in patients with Gastrointestinal and Solid Tumors.ocally Advanced Unresectable or Metastatic gastrointestinal StromalMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003497-14-ITBLUEPRINT MEDICINES CORPORATIO460
进行中（未招募）
1 期
_EUCTR2014-002560-33-FRICANCER180
进行中（未招募）
1 期
_EUCTR2014-002560-33-BEICANCER180
进行中（未招募）
1 期
PALbociclib rechallenge in hormone receptor-posItive/HER2-negative advanced breast cancer (PALMIRA)Hormone receptor-positive/HER2-negative Advanced Breast CancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2017-002781-48-DEMedica Scientia Innovation Research (MedSIR)198
进行中（未招募）
不适用
A observational study of efficacy and safety of medicinal drugs Dalteparin Sodium, solution for intravenous and subcutaneous administratioCTRI/2016/10/007400JSC Pharmasyntez190